Stephen E. Cooper Net Worth

The estimated Net Worth of Stephen E. Cooper is at least $545 Mille dollars as of 20 February 2014. Stephen Cooper owns over 18,851 units of Inogen Inc stock worth over $264,874 and over the last 11 years Stephen sold INGN stock worth over $280,503.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Cooper INGN stock SEC Form 4 insiders trading

Stephen has made over 1 trades of the Inogen Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Stephen sold 18,851 units of INGN stock worth $280,503 on 20 February 2014.

The largest trade Stephen's ever made was selling 18,851 units of Inogen Inc stock on 20 February 2014 worth over $280,503. On average, Stephen trades about 18,851 units every 0 days since 2014. As of 20 February 2014 Stephen still owns at least 22,913 units of Inogen Inc stock.

You can see the complete history of Stephen Cooper stock trades at the bottom of the page.

What's Stephen Cooper's mailing address?

Stephen's mailing address filed with the SEC is 326 BOLLAY DRIVE, , GOLETA, CA, 93117.

Insiders trading at Inogen Inc

Over the last 11 years, insiders at Inogen Inc have traded over $242,179,025 worth of Inogen Inc stock and bought 9,125 units worth $253,950 . The most active insiders traders include Holdings A/S Novo, Timothy Petersen e Raymond Huggenberger. On average, Inogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $321,391. The most recent stock trade was executed by Jason Somer on 1 June 2024, trading 577 units of INGN stock currently worth $6,670.

What does Inogen Inc do?

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take

Complete history of Stephen Cooper stock trades at Inogen Inc

Inogen Inc executives and stock owners

Inogen Inc executives and other stock owners filed with the SEC include:

• Scott Wilkinson,
  President, Chief Executive Officer, Director
• Alison Bauerlein,
  Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
• Bart Sanford,
  Executive Vice President, Operations
• Byron Myers,
  Executive Vice President of Marketing
• Brenton Taylor,
  Executive Vice President - Engineering
• Dr. Stanislav Glezer M.D., MBA,
  Exec. VP & CTO
• Alison Perry Bauerlein,
  Co-Founder
• Bart Sanford,
  Exec. VP of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Heather Rider,
  Independent Director
• R. Scott Greer,
  Independent Director
• Loren McFarland,
  Independent Director
• Benjamin Anderson-Ray,
  Independent Director
• Raymond Huggenberger,
  Independent Director
• Matt Bacso,
  IR Contact Officer
• Scott Beardsley,
  Independent Director
• Arron Retterer,
  Executive Vice President of Sales
• Jennifer Yi Boyer,
  Exec. VP & Chief HR Officer
• Agnes Lee,
  Sr. VP of Investor Relations & Strategic Planning
• Kristin A. Caltrider,
  Exec. VP, CFO & Treasurer
• Matthew Pigeon,
  Investor Relations Officer
• George J. Parr,
  Exec. VP & Chief Commercial Officer
• Jason Somer,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Matthew James Bacso C.F.A.,
  Investor Relations & Corp. Devel. Mang.
• Michael K. Sergesketter,
  Interim Chief Financial Officer
• Nabil Shabshab,
  CEO, Pres & Director
• Kevin M King,
  
• Matt Scribner,
  See Remarks
• George J Parr,
  Chief Commercial Officer
• William J Phd Link,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kristin A. Caltrider,
  EVP, CFO and Treasurer
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llclink William...,
  
• Ventures Ii Lp Arboretum Ve...,
  
• Stephen E. Cooper,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Holdings A/S Novo,
  10% owner
• Charles E Larsen,
  Director
• Timothy Petersen,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kevin Raymond Merrill Smith,
  CEO and President
• Kristen Miranda,
  Director
• Nabil Shabshab,
  CEO and President
• Stanislav Glezer,
  EVP, R&D & Chief Med. Officer
• Jason Somer,
  EVP, Gen. Counsel & Secretary
• Michael J. Bourque,
  EVP, CFO & Treasurer
• Elizabeth Mora,
  
• Thomas A. West,
  
• Mary Kay Ladone,
  
• Glenn S Boehnlein,
  
• Kevin P. Smith,
  EVP, Bus Dev, GC & Sec